

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**


# Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
GlaxoSmithKline (dostarlimab)	All Wales Therapeutics and Toxicology     Centre
<ul><li>Patient/carer groups</li><li>Black Health Agency for Equality</li></ul>	<ul><li>Allied Health Professionals Federation</li><li>Board of Community Health Councils in</li></ul>
Cancer Black Care	Wales
Cancer Equality	British National Formulary
Cancer 52	Care Quality Commission
Endometriosis Foundation  For the contribution in LIV	Department of Health - Northern Ireland     Department of Health - Northern Ireland
Endometriosis UK	Healthcare Improvement Scotland
<ul><li>Eve Appeal</li><li>Helen Rollason Cancer Charity</li></ul>	<ul> <li>Medicines and Healthcare products Regulatory Agency</li> </ul>
Independent Cancer Patients Voice	National Association of Primary Care
Macmillan Cancer Support	National Pharmacy Association
Maggie's Centres	NHS Confederation
Marie Curie	Scottish Medicines Consortium
Peaches Womb Cancer Trust	Welsh Government
<ul> <li>South Asian Health Foundation</li> </ul>	Welsh Health Specialised Services
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	
Wellbeing of Women	Possible comparator companies
Womb Cancer Support UK	Accord (carboplatin, paclitaxel, cisplatin,
Women's Health Concern	doxorubicin)
	Alliance Healthcare (cyclophosphamide,
Healthcare professional groups	paclitaxel)
Association of Anaesthetists	AstraZeneca (durvalumab, olaparib)
Association of Cancer Physicians	Bausch & Lomb (megestrol acetate)
Association of Surgeons of Great	Baxter Healthcare (cyclophosphamide)
Britain and Ireland	Bristol Myers Squibb Pharmaceuticals
British Association of Surgical	(paclitaxel)
Oncology	Consilient Health (carboplatin)
British Geriatrics Society	Fresenius Kabi (carboplatin, paclitaxel)
British Gynaecological Cancer Society	Hospira UK (carboplatin, paclitaxel)
British Institute of Radiology	<ul> <li>Johnson &amp; Johnson Innovative Medicine (doxorubicin)</li> </ul>

Provisional stakeholder list for the evaluation of dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

Issue date: September 2024



#### **Provisional Consultees Provisional Commentators (no right to** submit or appeal) Medac GmbH (doxorubicin) **British Oncology Pharmacy** Association Merck Sharp & Dohme British Psychosocial Oncology Society (pembrolizumab) British Society for Clinical Cytology Novartis (cisplatin, cyclophosphamide) British Society for Colposcopy and Pfizer (carboplatin, paclitaxel, cisplatin, Cervical Pathology doxorubicin, medroxyprogesterone Cancer Research UK acetate) National Forum of Gynaecological Sandoz (cyclophosphamide) Oncology Nurses Seacross Pharmaceuticals (paclitaxel, Royal College of Anaesthetists doxorubicin) Royal College of General Practitioners Teva UK (carboplatin, paclitaxel) Royal College of Nursing Royal College of Obstetricians and Relevant research groups Genomics England Gynaecologists Institute of Cancer Research Royal College of Pathologists MRC Clinical Trials Unit Royal College of Physicians National Institute for Health Research Royal College of Radiologists Royal College of Surgeons Associated Public Health groups Royal Pharmaceutical Society Public Health Wales Royal Society of Medicine UK Health Security Agency Society and College of Radiographers **UK Clinical Pharmacy Association UK Oncology Nursing Society** Others Department of Health and Social Care NHS England

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


### **Definitions:**

## **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

Issue date: September 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.